DIRS.INFO The most relevant business & tech news

☆ Mpox vaccination to begin in Congo next month
▼ + stars: | 2024-09-09 | by ( The Associated Press | ) www.nbcnews.com time to read: +2 min

A vaccination campaign against mpox in Congo will begin Oct. 2, authorities said Saturday, with workers focusing on the three most affected provinces first. Earlier this week, the first batch of mpox vaccines arrived in the capital of Congo, the center of the outbreak. The European Union countries pledged to donate more than 500,000 others, but the timeline for their delivery remained unclear. Most mpox infections in Congo and Burundi, the second most affected country, are in children under age 15. Congo issued an emergency approval of the vaccine, which has already been used in Europe and the United States in adults.

Persons: Cris Kacita Osako, Congo’s, Dr, Jean Kaseya, Laurent Muschel Organizations: mpox, Associated Press, Bavarian Nordic, European Union, Africa Center for Disease Control, World Health Organization, WHO, European Medicines Agency Locations: Congo, Equateur, South Kivu, Sankuru, Danish, European Union, Burundi, Europe, United States

The German share price index DAX graph is pictured at the Frankfurt stock exchange in Frankfurt, Germany, March 17, 2023. The pan-European STOXX 600 (.STOXX) closed up 0.1% ahead of inflation readings from Germany, China and the U.S. later this week, all likely to drive expectations on how long interest rates could remain high. Europe's aerospace and defence index (.SXPARO) hit a record high, rising 1.0%, with Italy's Leonardo (LDOF.MI) and London-listed Melrose (MRON.L) up 3.1% and 2.6% respectively. Major European bourses were mixed, with London's commodity-heavy FTSE 100 down 0.1%, while France's blue-chip CAC 40 index (.FCHI) rose 0.1%. Pressuring Germany's DAX (.GDAXI), Siemens Energy (ENR1n.DE) dropped 6.1%, having shuttled between gains and losses throughout the day.

Persons: Daniela Hathorn, Italy's Leonardo, Anthi Tsouvali, Germany's DAX, Shashwat Chauhan, Sruthi Shankar, Amruta, Varun, Alex Richardson Organizations: REUTERS, Staff, Defence, Siemens Energy, U.S, Aurubis AG, Capital.com, Bavarian, Melrose, State Street Global Markets, Thomson Locations: Frankfurt, Germany, China, Danish, London, U.S, Bengaluru

☆ US FDA approves first RSV vaccine from GSK
▼ + stars: | 2023-05-03 | by ( ) www.reuters.com time to read: +1 min

May 3 (Reuters) - The U.S. Food and Drug Administration has approved GSK Plc's (GSK.L) respiratory syncytial virus (RSV) vaccine, the British drugmaker said on Wednesday, making it the first shot to be cleared for protection against a common respiratory disease that can be fatal for older people. The vaccine was approved for people aged 60 and older, the company said. The approval makes GSK, which has been neck-and-neck with Pfizer (PFE.N) in RSV vaccine development, the first company to tap into a multi-billion-dollar market and puts it ahead of rivals such as Moderna Inc (MRNA.O) and Bavarian Nordic (BAVA.CO). Analysts have estimated the market for RSV vaccines to cross $10 billion by 2030. GSK expects the vaccine to be available before the next RSV season in the United States, Chief Commercial Officer Luke Miels told Reuters on Wednesday before the approval.

☆ Mpox outbreak was wake-up call for smallpox preparation, vaccine maker Bavarian Nordic says
▼ + stars: | 2023-04-25 | by ( Spencer Kimball | ) www.cnbc.com time to read: +8 min

Bavarian Nordic CEO Paul Chaplin said the rapid spread of mpox last year was a wake-up call for the company, which is based in Denmark. Bavarian Nordic's Jynneos vaccine is approved by the U.S. Food and Drug Administration to protect against both pathogens. Bavarian Nordic will finish delivering an order of 5 million Jynneos doses for the U.S government in the first half of this year. Bavarian Nordic estimates that the potential demand for the mpox vaccine could reach tens of millions of doses. "If you can reengineer a related virus like horsepox, you can engineer variola, which is the smallpox virus that infects humans," he said.

☆ CDC advisors recommend mpox vaccine for at-risk adults in future outbreaks
▼ + stars: | 2023-02-22 | by ( Spencer Kimball | ) www.cnbc.com time to read: +2 min

The Centers for Disease Control and Prevention's independent advisors on Wednesday unanimously recommended administering the two-dose Jynneos vaccine to adults at risk of mpox in the event of future outbreaks, following last year's unprecedented epidemic. "It's important to state that an mpox outbreak will be determined by public health authorities, and a single case may be considered an mpox outbreak at the discretion of the public health authority," said Dr. Pablo Sanchez, head of the CDC committee's mpox workgroup. "Local health departments, state health departments, federal can all make that determination of what is considered an outbreak," Rao said. The CDC advisors will meet again in June to discuss using the Jynneos vaccine for kids at risk of mpox in future outbreaks. The U.S. is currently offering the vaccine to adults and adolescents who are at risk in the current epidemic.

☆ Bavarian Nordic to buy travel vaccine portfolio for up to $380 mln
▼ + stars: | 2023-02-15 | by ( ) www.reuters.com time to read: +1 min

Feb 15 (Reuters) - Danish pharmaceuticals company Bavarian Nordic (BAVA.CO) has agreed to buy a portfolio of travel vaccines from Emergent BioSolutions Inc (EBS.N) for up to $380 million, it said on Wednesday after delivering an upbeat outlook for 2023. The company said it would acquire a typhoid fever vaccine, one against cholera and a Chikungunya virus treatment that is in Phase III trials. Bavarian Nordics makes the only approved mpox vaccine and started receiving massive orders last year as the virus became a global issue. The company expects 2023 revenue of about 6 billion Danish crowns ($863 million) against the 3.15 billion crowns in preliminary 2022 results, with 4.4 billion crowns coming from mpox and smallpox vaccined contracts alone. Earnings before interest, tax, depreciation and amortisation (EBITDA) are expected to reach 2.2 billion crowns this year, up from 329 million crowns in the preliminary results for 2022.

☆ European shares eye upbeat end to week on banks, healthcare boost
▼ + stars: | 2022-12-23 | by ( Amruta Khandekar | ) www.reuters.com time to read: +3 min

SummarySummary Companies STOXX 600 rises 0.2%Banks, healthcare firms gainBavarian Nordic at the top of STOXX 600Italian business morale rises in DecemberDec 23 (Reuters) - Europe's STOXX 600 edged higher on Friday, with gains in healthcare firms and banks putting the index on course to end the last week before Christmas on an upbeat note. The region-wide STOXX 600 (.STOXX) rose 0.2% at 0915 GMT and was bound for a 0.8% weekly advance. Morale amongst Italian businesses and consumers rose in December, data showed on Friday, although the manufacturing sector was more downbeat. On the economic data front, a report showed Spain's economy expanded 0.1% in the third quarter, slowing from a 2.0% growth rate in the previous three-month period. Among STOXX 600 sectors, shares of retailers (.SXRP) rose 0.6% to lead gains.

☆ United States to end mpox emergency declaration
▼ + stars: | 2022-12-02 | by ( ) www.reuters.com time to read: +3 min

Dec 2 (Reuters) - Mpox is expected to no longer be considered a public health emergency in the United States from Feb. 1, 2023, the U.S. health department said on Friday. The months-long declaration was meant to tackle the largest-ever outbreak of cases in the country. The WHO label, a "public health emergency of international concern (PHEIC)", is designed to trigger a coordinated international response and could unlock funding to collaborate on sharing vaccines and treatments. The disease, which is endemic in parts of Africa, began spreading in Europe earlier this year before moving to the United States. More than 29,000 cases have been reported in the United States in the outbreak this year, including two deaths, according to government data.

In the West, only about 10 people have died of monkeypox this year, figures from the U.S. CDC show. No monkeypox vaccines are publicly available in Africa. But those failures are being repeated a year on with monkeypox, the health workers consulted by Reuters said. Congo health minister Jean-Jacques Mbungani told Reuters Congo was in talks with the WHO to buy vaccines, but no formal request had been made. A WHO spokeswoman said that in the absence of available vaccines, countries should instead focus on surveillance and contact tracing.

☆ New RSV vaccines may soon put an end to rough seasons
▼ + stars: | 2022-10-31 | by ( Brenda Goodman | ) edition.cnn.com time to read: +15 min

The monoclonal antibody, Synagis, is given monthly during RSV season to protect preemies and other high-risk babies. In the failed RSV vaccine trial, the chemical the researchers used to deactivate the virus denatured its proteins – essentially flattening them. Four companies have RSV vaccines for adults in the final phases of human trials: Pfizer and GSK are testing vaccines for pregnant women as well as seniors. Janssen, Pfizer and GSK each appear effective at preventing infections in adults for the first RSV season after the vaccine. The vaccines for pregnant women are meant to get newborns through their first RSV season.

☆ With no monkeypox vaccine at home, frustrated Mexicans go abroad
▼ + stars: | 2022-10-17 | by ( Brendan O'Boyle | ) www.reuters.com time to read: +3 min

MEXICO CITY, Oct 17 (Reuters) - As monkeypox continues to impact gay and bisexual men in dozens of countries around the world, at-risk Mexicans are going abroad for vaccines they say their government has not bothered to make available at home. Register now for FREE unlimited access to Reuters.com RegisterHerbel, 38, said he wanted the vaccine because half of his friends currently have or have had monkeypox. Mexico City resident Juan David Zuluaga, 32, flew to Tijuana last week to get vaccinated across the U.S.-Mexico border in San Diego. Mexico's government has reported 2,147 confirmed cases of monkeypox since May, a number advocates in the gay community say far undercounts cases. "Those with visas and money will get vaccinated and those without will have to resign themselves to eventually getting monkeypox," Baruch said.

Workers sit outside of D.C. Health's first monkeypox vaccination clinic, which is administering the first Jynneos vaccine doses distributed in the U.S. capital, in Washington, U.S., June 28, 2022. REUTERS/Gavino GarayWASHINGTON, Sept 28 (Reuters) - At risk people nationwide will now be able to get Bavarian Nordic's (BAVA.CO) Jynneos monkeypox vaccine before being exposed to the disease, U.S. Centers for Disease Prevention and Control (CDC) Director Rochelle Walensky said on Wednesday. At risk individuals will now be eligible to receive the vaccine before exposure as the CDC shifts to a Pre-Exposure Prophylaxis (PrEP) strategy, Wallensky said. Monkeypox is transmitted through close contact with an infected person, such as via sexual activity, or with the skin blisters associated with the disease. People with jobs that put them at risk of exposure, such as healthcare workers, were already eligible for vaccination against monkeypox.

☆ A single dose of monkeypox vaccine provides some protection against infection, CDC says
▼ + stars: | 2022-09-28 | by ( Spencer Kimball | ) www.cnbc.com time to read: +2 min

The data indicate that even a single dose of the vaccine provides some initial protection against infection as soon as two weeks after the shot, Walensky said. The Jynneos vaccine, manufactured by the Danish company Bavarian Nordic, is administered in two doses 28 days apart. Walensky said although the data on a single dose is promising, lab studies have demonstrated that the immune protection is highest two weeks after the second dose. "What we have right now is data on how well and how our vaccine is working after as single dose. What we don't yet have is what happens after a second dose and how durable that protection is," Walensky said.

☆ Portugal approves preventive monkeypox vaccination for risk groups
▼ + stars: | 2022-09-21 | by ( ) www.reuters.com time to read: +1 min

A woman holds a mock-up vial labeled "Monkeypox vaccine" and medical syringe in this illustration taken, May 25, 2022. REUTERS/Dado Ruvic/Illustration/File PhotoLISBON, Sept 21 (Reuters) - Portugal's health authority widened its monkeypox vaccination strategy to include preventive shots for groups most at risk and approved the use of smaller doses, an approach known as "dose-sparing", due to limited supplies, it said on Wednesday. Register now for FREE unlimited access to Reuters.com RegisterThe preventive vaccination logistics strategy will be managed at a regional level, after identifying eligible citizens in a specialist consultation. With the new strategy, Portugal follows in the footsteps neighbouring Spain or Britain, which also approved the use of smaller doses of the monkeypox vaccine following a European Medicines Agency decision. Portugal has received 2,700 doses of the Bavarian Nordic's (BAVA.CO) Imvanex vaccine in July and has started vaccinating close contacts.

☆ U.S. monkeypox outbreak is slowing, CDC director says
▼ + stars: | 2022-09-14 | by ( Ashley Capoot | ) www.cnbc.com time to read: +1 min

Monkeypox continues to spread across the U.S., but the pace of new cases has slowed over the last several weeks, Dr. Rochelle Walensky, director of the Centers for Disease Control and Prevention, told lawmakers Wednesday. The U.S. is working to contain the largest monkeypox outbreak in the world, with more than 22,600 cases across all 50 states, Washington D.C. and Puerto Rico, according to data from the CDC. There has been one confirmed death in the U.S. as a result of the disease, according to Walensky. The Jynneos vaccine, manufactured by Danish biotech company Bavarian Nordic, is the only approved monkeypox vaccine in the U.S. Two doses are administered 28 days apart, and CDC officials say it's crucial for people at risk to receive the second shot. It takes two weeks after the second dose for the immune system to reach its peak response.

Search resuls for: "Bavarian Nordic"

15 mentions found